-
Mashup Score: 0The promise of CAR-T therapy in adult ALL and future outlooks - 1 year(s) ago
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares some insights into the value of CAR-T therapy and other immunotherapeutic…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Novel CAR-T constructs emerging in multiple myeloma for patients who experience loss of BCMA - 1 year(s) ago
In this video, Hermann Einsele, MD, FRCP, University Hospital of WĆ¼rzburg, WĆ¼rzburg, Germany, briefly discusses CAR-T constructs emerging for patients…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#CART23 | @H_Einsele of @Uni_WUE highlights novel CAR-T constructs emerging in multiple myeloma for patients who experience loss of BCMA: šhttps://t.co/6raX31F0WJš @TheEBMT @EHA_Hematology #MMsm #HemOnc #ImmunoOnc #CARTcell #tcellrx
-
-
Mashup Score: 0
Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, shares some insights into a study which evaluated the impact of the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
How can changes in the gut microbiome impact patient response to CAR-T therapy? @MarcoRuella (@Penn) shares some insights: š„: https://t.co/4XQvPaS7sy @TheEBMT @EHA_Hematology #CART23 #HemOnc #ImmunoOnc #CARTcell
-
-
Mashup Score: 2Clinical indications for CAR-T therapy in DLBCL & the possibility of moving CAR-T into earlier lines - 1 year(s) ago
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses clinical indications for CAR-T therapy…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Find out more about clinical indications for CAR-T therapy in DLBCL & the possibility of moving CAR-T into earlier lines in our interview with @AnnaSureda5: š„: https://t.co/gZjymeIPdP @TheEBMT @EHA_Hematology #CART23 #LymSM #DLBCL #ImmunoOnc #CARTcell #HemOnc
-
-
Mashup Score: 1CART 2023 - Program - 1 year(s) ago
Abstract title:Ā Three-year Follow-up of Brexucabtagene Autoleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy, in Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL) in ZUMA-3 T. Hadjivassileva1, B.D. Shah2, A. Ghobadi3, O.O. Oluwole4, A.C. Logan5, N. Boissel6, R.D. Cassaday7, T. Leguay8, M.R. Bishop9, M.S. Topp10, D. Tzachanis11, K.M. OāDwyer12, M.L….
Source: cart2023.abstractserver.comCategories: Hem/Oncs, Latest HeadlinesTweet-
ZUMA-3 updated results for brexu-cel in ALL: 3 year OS 47% median RFS 11.6 months median DOR 18.6 months (20 if not censored for alloSCT) #leusm #CART23 https://t.co/sK2ldQdoeH #Tandem23
-
-
Mashup Score: 0Real-world experiences with ide-cel in R/R multiple myeloma - 1 year(s) ago
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, discusses real-world experiences with idecabtagene vicleucel (ide-cel) for the treatment of patients…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Doris Hansen (@MoffittNews) shares some insights into real-world experiences with ide-cel in patients with R/R multiple myeloma: š„: https://t.co/PP0Q5yahci @TheEBMT @EHA_Hematology #CART23 #CARTcell #MMsm #ImmunoOnc
-
-
Mashup Score: 0Tisagenlecleucel Shows āDurable Efficacy and Favorable Safetyā in Phase II ELARA Trial | Blood Cancers Today - 1 year(s) ago
Tisagenlecleucel, a CD19-directed CAR T-cell therapy, demonstrated ādurable efficacy and favorable safetyā in patients with relapsed/refractory follicular lymphoma.
Source: Blood Cancers TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tisagenlecleucel had ādurable efficacy and favorable safetyā in R/R follicular lymphoma, according to data from the phase II ELARA trial presented by Catherine Thieblemont, MD, PhD, of @HopSaintLouis, during the @TheEBMT-@EHA_Hematology #CART23 meeting. https://t.co/6EChXZB4PQ
-
-
Mashup Score: 0Strategies to minimize the occurrence of CRS and ICANS in patients treated with CAR-T therapy - 1 year(s) ago
In this video, Eleni Gavriilaki, MD, PhD, G. Papanikolaou Hospital, Thessaloniki, Greece, comments on the importance of improving strategies to…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Find out more about the importance of improving strategies to minimize the occurrence of CRS after CAR-T therapy in our exclusive interview with @elenicelli: š„: https://t.co/h327Po1drk @TheEBMT @EHA_Hematology #CART23 #CARTcell #HemOnc #ImmunoOnc #tcellrx
-
-
Mashup Score: 2Exploring the potential role of CD7-targeting CAR-T cells for the treatment of T-ALL - 1 year(s) ago
Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, shares some insights into the promise of CD7-targeting CAR-T therapies for…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#CART23 | @MaxMamonkin discusses the potential of exploring CD7-targeting CAR-T cells for the treatment of T-ALL: šhttps://t.co/0JUvPl2IORš @TheEBMT @EHA_Hematology #CARTcell #ALLsm #LeuSM #ImmunoOnc #HemOnc
-
-
Mashup Score: 0KarMMa-3 Results 'Support Use' of Idecabtagene Vicleucel in Triple Class-Exposed Multiple Myeloma | Blood Cancers Today - 1 year(s) ago
Idecabtagene vicleucel led to ādeeper and more durable responsesā than standard regimens in patients with triple classāexposed relapsed/refractory multiple myeloma in KarMMa-3.
Source: Blood Cancers TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
KarMMa-3 results presented by @paurotero of @ClinicaNavarra at @TheEBMT-@EHA_Hematology #CART23 "support use of ide-cel in pts w/early line relapse and triple class-exposed relapsed/refractory multiple myeloma, a pt population with poor survival outcomes." https://t.co/oplfJVXwNA https://t.co/QDfTTS1XnG
-
#CART23 | @Mohty_EBMT discusses the promise of CAR-T therapy and other immunotherapeutic agents in the treatment of adult ALL. Watch his exclusive interview here: š„: https://t.co/oskous4AYZ @TheEBMT @EHA_Hematology #CARTcell #LeuSM #ALLsm #HemOnc #ImmunoOnc #tcellrx #BMTsm